1. Bammer C, Sperr WR et al. *Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes.* - J Geriatr Oncol -; 5 (3); 299-306


40. Saras.E., Strom, Viviane velaz Bruno. Epidemiology of myelodysplastic syndromes, Houston; seminars in hematology 45.8-13, 2008 Elsivier Anderson cancer center.


42. Yau Du, Jon Fryzele, Mikkael A. Smoking and alcohol as risk factors for MDS. Leukemia research 2009 10 september.


79. Gerds AT et al. Albumin as a prognostic marker in MDS - still relevant after all these years. Commentary for Leukemia and lymphoma on
hypoalbuminuria is a surrogate marker of poor prognosis in MDS even when adjusted with comorbidities. Leuk Lymphoma. 2015 Apr 22:1-5.


94. Dreyfus B. Preleukemic states. I. Definition and classification. II. Refractory anemia with an excess of myeloblasts in the bone marrow


106. Wei J , Chen Y .Scoring analysis on prognosis of 63 patients with MDS , Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Apr;16(2):305-11


